Lansoprazole inhibits the development of sessile serrated lesions by inducing G1 arrest via Skp2/p27 signaling pathway

被引:3
|
作者
Kawaguchi, Tomoyuki [1 ]
Okamoto, Koichi [1 ]
Fujimoto, Shota [1 ]
Bando, Masahiro [1 ]
Wada, Hironori [1 ]
Miyamoto, Hiroshi [1 ]
Sato, Yasushi [2 ]
Muguruma, Naoki [1 ]
Horimoto, Katsuhisa [3 ,4 ]
Takayama, Tetsuji [1 ]
机构
[1] Tokushima Univ, Inst Biomed Sci, Dept Gastroenterol & Oncol, Grad Sch, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan
[2] Tokushima Univ, Dept Community Med Gastroenterol & Oncol, Grad Sch Biomed Sci, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan
[3] AIST, Mol Profiling Res Ctr Drug Discovery Molprof, 2-3-26 Aomi,Koto Ku, Tokyo 1350064, Japan
[4] SOCIUM Inc, 2-4-7 Aomi,Koto ku, Tokyo 1350064, Japan
关键词
Sessile serrated lesion; Chemoprevention; Connectivity map; Organoid; Lansoprazole; PROTON PUMP INHIBITORS; HUMAN COLON; DNA METHYLATION; BRAF MUTATION; CANCER CELLS; POLYPS; PROSTATE; GROWTH; TUMORS;
D O I
10.1007/s00535-023-02052-0
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BackgroundAlthough the serrated-neoplasia pathway reportedly accounts for 15-30% of colorectal cancer (CRC), no studies on chemoprevention of sessile serrated lesions (SSLs) have been reported. We searched for effective compounds comprehensively from a large series of compounds by employing Connectivity Map (CMAP) analysis of SSL-specific gene expression profiles coupled with in vitro screening using SSL patient-derived organoids (PDOs), and validated their efficacy using a xenograft mouse model of SSL.MethodsWe generated SSL-specific gene signatures based on DNA microarray data, and applied them to CMAP analysis with 1309 FDA-approved compounds to select candidate compounds. We evaluated their inhibitory effects on SSL-PDOs using a cell viability assay. SSL-PDOs were orthotopically transplanted into NOG mice for in vivo evaluation. The signal transduction pathway was evaluated by gene expression profile and protein expression analysis.ResultsWe identified 221 compounds by employing CMAP analysis of SSL-specific signatures, which should cancel the gene signatures, and narrowed them down to 17 compounds. Cell viability assay using SSL-PDOs identified lansoprazole as having the lowest IC50 value (47 mu M) among 17 compounds. When SSL-PDO was orthotopically transplanted into murine intestinal tract, the tumor grew gradually. Administration of lansoprazole to mice inhibited the growth of SSL xenograft whereas the tumor in control mice treated with vehicle alone grew gradually over time. The Ki67 index in xenograft lesions from the lansoprazole group was significantly lower compared with the control group. Cell cycle analysis of SSL-PDOs treated with lansoprazole exhibited a significant increase in G1 phase cell population. Microarray and protein analysis revealed that lansoprazole downregulated Skp2 expression and upregulated p27 expression in SSL-PDOs.ConclusionsOur data strongly suggest that lansoprazole is the most effective chemopreventive agent against SSL, and that lansoprazole induces G1 cell cycle arrest by downregulating Skp2 and upregulating p27 in SSL cells.
引用
收藏
页码:11 / 23
页数:13
相关论文
共 50 条
  • [1] Lansoprazole inhibits the development of sessile serrated lesions by inducing G1 arrest via Skp2/p27 signaling pathway
    Tomoyuki Kawaguchi
    Koichi Okamoto
    Shota Fujimoto
    Masahiro Bando
    Hironori Wada
    Hiroshi Miyamoto
    Yasushi Sato
    Naoki Muguruma
    Katsuhisa Horimoto
    Tetsuji Takayama
    Journal of Gastroenterology, 2024, 59 : 11 - 23
  • [2] Egg antigen p40 of Schistosoma japonicum promotes senescence in activated hepatic stellate cells via SKP2/P27 signaling pathway
    Tianhua Xu
    Jinling Chen
    Dandan Zhu
    Liuting Chen
    Jianxin Wang
    Xiaolei Sun
    Bin Hu
    Yinong Duan
    Scientific Reports, 7
  • [3] Egg antigen p40 of Schistosoma japonicum promotes senescence in activated hepatic stellate cells via SKP2/P27 signaling pathway
    Xu, Tianhua
    Chen, Jinling
    Zhu, Dandan
    Chen, Liuting
    Wang, Jianxin
    Sun, Xiaolei
    Hu, Bin
    Duan, Yinong
    SCIENTIFIC REPORTS, 2017, 7
  • [4] Correlation of expression of galectin-3, skp2, p27 and cyclin D1 in benign and malignant thyroid lesions
    Hong, Soon Auck
    Hong, Min Eui
    Kwon, Gui Young
    Kim, Mi Kyung
    KOREAN JOURNAL OF PATHOLOGY, 2008, 42 (03) : 134 - 139
  • [5] Downregulation of Skp2 and p27/Kip1 synergistically induces apoptosis in T98G glioblastoma cells
    Sang Hyun Lee
    Frank McCormick
    Journal of Molecular Medicine, 2005, 83 : 296 - 307
  • [6] Downregulation of Skp2 and p27/Kip1 synergistically induces apoptosis in T98G glioblastoma cells
    Lee, SH
    McCormick, F
    JOURNAL OF MOLECULAR MEDICINE-JMM, 2005, 83 (04): : 296 - 307
  • [7] p107 inhibits G1 to S phase progression by downregulating expression of the F-box protein Skp2
    Rodier, G
    Makris, C
    Coulombe', P
    Scime, A
    Nakayama, K
    Nakayama, KI
    Meloche, S
    JOURNAL OF CELL BIOLOGY, 2005, 168 (01): : 55 - 66
  • [8] Knockdown of AMPK α2 Promotes Pulmonary Arterial Smooth Muscle Cells Proliferation via mTOR/Skp2/p27Kip1 Signaling Pathway
    Ke, Rui
    Liu, Lu
    Zhu, Yanting
    Li, Shaojun
    Xie, Xinming
    Li, Fangwei
    Song, Yang
    Yang, Lan
    Gao, Li
    Li, Manxiang
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2016, 17 (06)
  • [9] Nuclear pro-IL-16 regulation of T cell proliferation:: p27KIP1-dependent G0/G1 arrest mediated by inhibition of Skp2 transcription
    Center, DM
    Cruikshank, WW
    Zhang, YJ
    JOURNAL OF IMMUNOLOGY, 2004, 172 (03): : 1654 - 1660
  • [10] Notch1 modulates timing of G1-S progression by inducing SKP2 transcription and p27Kip1 degradation
    Sarmento, LM
    Huang, H
    Limon, A
    Gordon, W
    Fernandes, J
    Tavares, MJ
    Miele, L
    Cardoso, AA
    Classon, M
    Carlesso, N
    JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 202 (01): : 157 - 168